Saudi Arabia’s NEOM has partnered with Paradromics Inc., a U.S.-based leader in brain-computer interface (BCI) technology, to establish a regional Center of Excellence. This collaboration aims to develop therapies restoring mobility, speech, and cognitive functions for patients with neurological impairments, according to a report by Bloomberg. The center will drive clinical research and position NEOM as MENA’s premier hub for BCI innovation.
Paradromics plans U.S. human trials for its Connexus BCI system in late 2025, with parallel testing in Saudi Arabia. CEO Matt Angle emphasized readiness to expand trials globally, prioritizing patients who lost speech due to ALS, strokes, or spinal injuries. The implant decodes neural signals via AI, enabling thought-controlled digital communication.
Vision 2030 Drives Health Sector Transformation
This partnership aligns with Crown Prince Mohammed bin Salman’s Vision 2030 to diversify Saudi Arabia’s economy and elevate healthcare outcomes. NEOM’s Health and Well-Being sector head, Dr. Mahmoud Al-Yamany, highlighted the initiative’s potential to address paralysis and chronic pain through cutting-edge neurotech.
Paradromics joins Neuralink, Synchron, and Precision Neuroscience in the competitive BCI race. Unlike Neuralink’s recent human implants, Paradromics’ FDA-designated Breakthrough Device focuses on medical applications before consumer use. NEOM’s investment underscores its strategy to lead in disruptive technologies, fostering job creation and global investor engagement.
Funding and Future Roadmap
While financial terms remain undisclosed, Paradromics previously secured $33 million in funding and FDA approvals. The company’s CEO Matt Angle confirmed plans to expand mental health applications, including mood disorder and addiction treatments, post-initial trials.
NEOM’s bold healthcare vision mirrors its Red Sea sustainability goals, integrating AI and renewable energy into its innovation ecosystem. As global interest in BCIs surges, this alliance positions Saudi Arabia at the forefront of neurotech’s trillion-dollar potential.
